Bo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Wang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Austin Stellpflug
Marquette University and the Medical College of Wisconsin
12 shared publications- Shue Wang
Department of Chemistry, Chemical and Biomedical Engineering, University of New Haven, West Haven, CT, 06516, USA
6 shared publications Rongxue Wu
University of Chicago
5 shared publicationsAmit Joshi
Marquette University and the Medical College of Wisconsin
4 shared publicationsJustin Caron
Department of Chemistry, Chemical and Biomedical Engineering, University of New Haven, West Haven, CT 06516, USA
4 shared publicationsLinxia Gu
Florida Institute of Technology
4 shared publications
Latest Publications
- 11 November 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18  (4) , 045027
Optimizing release dynamics of bone-derived nanoparticles for enhanced in vivo fluorescence monitoring and bone regeneration in craniofacial repair
Craniofacial bone defects, particularly alveolar clefts, pose significant clinical challenges in pediatric patients due to complex anatomy and the limitations of current grafting options. Although autologous bone grafts remain the clinical gold standard, their use is restricted by donor-site morbidity, limited tissue availability, high cost, and risks such as infection, chronic pain, and functional impairment. Decellularized and demineralized bone matrix (DDBM) offers an attractive alternative but lacks controlled drug-release capability and cannot be monitored in real time in patients. To address these limitations, we developed indocyanine green–encapsulated bone-derived nanoparticles (ICG/BPs) from porcine DDBM, combining the intrinsic osteoinductive and osteoconductive properties of DDBM with near-infrared (NIR) imaging functionality. In this study, we fabricated two ICG/BP formulations, crosslinked (X-ICG/BP) and uncrosslinked (UnX-ICG/BP), and compared their in vitro degradation, release profiles, and in vivo performance in a rat model of cavity-type alveolar defects. Crosslinking improved particle stability and prolonged ICG release, and NIR imaging enabled real-time, non-invasive monitoring of particle degradation and retention within the defect. Additionally, both ICG/BP formulations supported bone regeneration, with X-ICG/BPs demonstrating greater regeneration, tissue organization, and vascularization. Overall, these findings highlight the tunability and theranostic potential of ICG/BPs and support their continued development as an image-guided functional biomaterial for craniofacial bone repair.
- 11 November 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18  (4) , 045027
Optimizing release dynamics of bone-derived nanoparticles for enhanced in vivo fluorescence monitoring and bone regeneration in craniofacial repair
Craniofacial bone defects, particularly alveolar clefts, pose significant clinical challenges in pediatric patients due to complex anatomy and the limitations of current grafting options. Although autologous bone grafts remain the clinical gold standard, their use is restricted by donor-site morbidity, limited tissue availability, high cost, and risks such as infection, chronic pain, and functional impairment. Decellularized and demineralized bone matrix (DDBM) offers an attractive alternative but lacks controlled drug-release capability and cannot be monitored in real time in patients. To address these limitations, we developed indocyanine green–encapsulated bone-derived nanoparticles (ICG/BPs) from porcine DDBM, combining the intrinsic osteoinductive and osteoconductive properties of DDBM with near-infrared (NIR) imaging functionality. In this study, we fabricated two ICG/BP formulations, crosslinked (X-ICG/BP) and uncrosslinked (UnX-ICG/BP), and compared their in vitro degradation, release profiles, and in vivo performance in a rat model of cavity-type alveolar defects. Crosslinking improved particle stability and prolonged ICG release, and NIR imaging enabled real-time, non-invasive monitoring of particle degradation and retention within the defect. Additionally, both ICG/BP formulations supported bone regeneration, with X-ICG/BPs demonstrating greater regeneration, tissue organization, and vascularization. Overall, these findings highlight the tunability and theranostic potential of ICG/BPs and support their continued development as an image-guided functional biomaterial for craniofacial bone repair.
- 17 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114409
Nanoparticle-mediated bone regeneration: From molecular mechanisms to clinical translation
- 17 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114409
Nanoparticle-mediated bone regeneration: From molecular mechanisms to clinical translation
- 15 September 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16  (5) , 1547-1560
Image-guided in vivo evaluation and comparison of bone-targeting peptides for therapeutic intervention
Hydroxyapatite (HA)-binding peptides hold strong potential for bone-targeted therapies due to their high affinity for mineralized tissues. However, most existing studies have primarily focused on in vitro binding characterization, offering limited insight into their in vivo biodistribution and bone-binding performance. In this study, we evaluated the in vivo behavior of four HA-binding peptides, including D8, E8, YD8, and YE8, using fluorescence imaging to assess biodistribution in both healthy and pathological bone environments. In healthy animals, D8 showed the strongest bone-binding capacity, with prominent localization in the skull, femur, and tibia, while YD8 exhibited moderate binding. E8 and YE8 showed more limited localization, influenced by peptide dosage and binding kinetics. In pathological models, including tibial defects and osteogenesis imperfecta (OIM) mice, D8 and YD8 preferentially accumulated in compromised bone regions, highlighting their potential utility in targeting diseased bone microenvironments. Fluorescence imaging combined with spectral unmixing algorithms enabled effective visualization and quantification of peptide localization and distribution. These findings emphasize the value of in vivo studies for advancing the therapeutic and diagnostic applications of HA-binding peptides. The results provide a foundation for optimizing peptide design to improve specificity and efficacy in bone repair and regeneration. Graphical Abstract Translational Impact Statement: This study advances the development of bone-targeted therapeutics by identifying HA-binding peptides, particularly D8 and YD8, with strong affinity for both normal and diseased bone tissue. Through fluorescent imaging, we demonstrate their selective accumulation in pathological bone, highlighting their potential for targeted drug delivery and diagnostics. These findings support the clinical translation of peptide-based strategies to enhance precision in treating skeletal disorders, offering a foundation for improved therapies in conditions such as osteoporosis, bone metastases, and radiation-induced bone damage.
- 15 September 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16  (5) , 1547-1560
Image-guided in vivo evaluation and comparison of bone-targeting peptides for therapeutic intervention
Hydroxyapatite (HA)-binding peptides hold strong potential for bone-targeted therapies due to their high affinity for mineralized tissues. However, most existing studies have primarily focused on in vitro binding characterization, offering limited insight into their in vivo biodistribution and bone-binding performance. In this study, we evaluated the in vivo behavior of four HA-binding peptides, including D8, E8, YD8, and YE8, using fluorescence imaging to assess biodistribution in both healthy and pathological bone environments. In healthy animals, D8 showed the strongest bone-binding capacity, with prominent localization in the skull, femur, and tibia, while YD8 exhibited moderate binding. E8 and YE8 showed more limited localization, influenced by peptide dosage and binding kinetics. In pathological models, including tibial defects and osteogenesis imperfecta (OIM) mice, D8 and YD8 preferentially accumulated in compromised bone regions, highlighting their potential utility in targeting diseased bone microenvironments. Fluorescence imaging combined with spectral unmixing algorithms enabled effective visualization and quantification of peptide localization and distribution. These findings emphasize the value of in vivo studies for advancing the therapeutic and diagnostic applications of HA-binding peptides. The results provide a foundation for optimizing peptide design to improve specificity and efficacy in bone repair and regeneration. Graphical Abstract Translational Impact Statement: This study advances the development of bone-targeted therapeutics by identifying HA-binding peptides, particularly D8 and YD8, with strong affinity for both normal and diseased bone tissue. Through fluorescent imaging, we demonstrate their selective accumulation in pathological bone, highlighting their potential for targeted drug delivery and diagnostics. These findings support the clinical translation of peptide-based strategies to enhance precision in treating skeletal disorders, offering a foundation for improved therapies in conditions such as osteoporosis, bone metastases, and radiation-induced bone damage.
- 11 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8  (9) , 8172-8185
Transforming Human Amniotic Membrane into Nanoparticles: An Approach for Cardiac Delivery Systems
Cardiovascular disease remains the leading cause of death worldwide, with heart failure due to irreversible damage to heart muscle cells posing a major therapeutic challenge. Although current surgical and pharmacological interventions offer some benefits, there is an urgent need for innovative strategies to promote cardiac repair and regeneration. Recent efforts have focused on developing cost-effective, minimally invasive therapies that use controlled delivery systems to precisely target therapeutic agents, such as drugs, genes, or cells, while enhancing efficacy and minimizing side effects. Nanoparticles (NPs) have emerged as a promising solution, offering targeted delivery with reduced toxicity. In this study, we developed amniotic membrane-derived NPs (AMPs) from decellularized human amniotic membrane (DAM). The resulting AMPs exhibited nanoscale size, mild positive surface charge, and a sustained drug-release profile, making them well-suited for cardiac applications. Encapsulation of a fluorescent dye demonstrated their efficient drug-loading capacity and potential for noninvasive imaging. In vitro and in vivo evaluations confirmed excellent biocompatibility, minimal cytotoxicity, no observable inflammatory responses, and superior retention in cardiac tissue compared to free agents. These findings position AMPs as a promising platform for targeted cardiac drug delivery, offering specificity, safety, and controlled release for next-generation heart therapies.
- 11 August 2025
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8  (9) , 8172-8185
Transforming Human Amniotic Membrane into Nanoparticles: An Approach for Cardiac Delivery Systems
Cardiovascular disease remains the leading cause of death worldwide, with heart failure due to irreversible damage to heart muscle cells posing a major therapeutic challenge. Although current surgical and pharmacological interventions offer some benefits, there is an urgent need for innovative strategies to promote cardiac repair and regeneration. Recent efforts have focused on developing cost-effective, minimally invasive therapies that use controlled delivery systems to precisely target therapeutic agents, such as drugs, genes, or cells, while enhancing efficacy and minimizing side effects. Nanoparticles (NPs) have emerged as a promising solution, offering targeted delivery with reduced toxicity. In this study, we developed amniotic membrane-derived NPs (AMPs) from decellularized human amniotic membrane (DAM). The resulting AMPs exhibited nanoscale size, mild positive surface charge, and a sustained drug-release profile, making them well-suited for cardiac applications. Encapsulation of a fluorescent dye demonstrated their efficient drug-loading capacity and potential for noninvasive imaging. In vitro and in vivo evaluations confirmed excellent biocompatibility, minimal cytotoxicity, no observable inflammatory responses, and superior retention in cardiac tissue compared to free agents. These findings position AMPs as a promising platform for targeted cardiac drug delivery, offering specificity, safety, and controlled release for next-generation heart therapies.
- 3 July 2025
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37  (3/4) , 753-759
Using Digested and Lyophilized Bone Matrices to Enhance Retention and Sustained Release of BMP-2 for Bone Regeneration
Background: Human recombinant bone morphogenetic protein 2 (rhBMP-2) is an FDA-approved growth factor that is shown to induce new bone formation but includes safety risks like inflammation and ectopic bone formation. Research indicates that a prolonged, controlled release of rhBMP-2 enhances bone healing with fewer side effects than short-term release. Collagen sponges, commonly used for this purpose, have drawbacks including poor structural stability and inadequate release profiles. Current research is focused on improving rhBMP-2 delivery strategies, particularly for pediatric patients where its use is considered off-label. Methods: The authors' previous study developed a sponge-like gellable bone matrix from decellularized, demineralized, and enzymatically digested porcine bone that demonstrated both biocompatibility and bone regenerative capabilities. This study expands our previous work by infusing synthetic BMP2 (sBMP2) into digested and lyophilized bone matrix (DLBM) and stabilizing it with glutaraldehyde (GL) crosslinking, referred to as DLBM/sBMP2/GL scaffold. The authors evaluate the release of sBMP2 in vitro from within the DLBM post stabilization, and the overall effectiveness of the DLBM/sBMP2/GL scaffold at stimulating bone growth in vivo using a nonhealing, surgically created tibial defect in a small animal model. Results: The DLBM/sBMP2/GL scaffold offers a prolonged and sustained release of sBMP2 in vitro and demonstrates biocompatibility and osteogenicity in vivo, resulting in substantial bone regeneration based on the gradual scaffold degradation with the sustained release of sBMP2. Conclusions: The resulting DLBM/sBMP2/GL scaffold provides a promising alternative grafting option for pediatric patients, offering improved safety and efficacy over existing methods. This innovative approach addresses the need for better rhBMP-2 delivery systems, potentially expanding its use in pediatric bone healing applications.
- 3 July 2025
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37  (3/4) , 753-759
Using Digested and Lyophilized Bone Matrices to Enhance Retention and Sustained Release of BMP-2 for Bone Regeneration
Background: Human recombinant bone morphogenetic protein 2 (rhBMP-2) is an FDA-approved growth factor that is shown to induce new bone formation but includes safety risks like inflammation and ectopic bone formation. Research indicates that a prolonged, controlled release of rhBMP-2 enhances bone healing with fewer side effects than short-term release. Collagen sponges, commonly used for this purpose, have drawbacks including poor structural stability and inadequate release profiles. Current research is focused on improving rhBMP-2 delivery strategies, particularly for pediatric patients where its use is considered off-label. Methods: The authors' previous study developed a sponge-like gellable bone matrix from decellularized, demineralized, and enzymatically digested porcine bone that demonstrated both biocompatibility and bone regenerative capabilities. This study expands our previous work by infusing synthetic BMP2 (sBMP2) into digested and lyophilized bone matrix (DLBM) and stabilizing it with glutaraldehyde (GL) crosslinking, referred to as DLBM/sBMP2/GL scaffold. The authors evaluate the release of sBMP2 in vitro from within the DLBM post stabilization, and the overall effectiveness of the DLBM/sBMP2/GL scaffold at stimulating bone growth in vivo using a nonhealing, surgically created tibial defect in a small animal model. Results: The DLBM/sBMP2/GL scaffold offers a prolonged and sustained release of sBMP2 in vitro and demonstrates biocompatibility and osteogenicity in vivo, resulting in substantial bone regeneration based on the gradual scaffold degradation with the sustained release of sBMP2. Conclusions: The resulting DLBM/sBMP2/GL scaffold provides a promising alternative grafting option for pediatric patients, offering improved safety and efficacy over existing methods. This innovative approach addresses the need for better rhBMP-2 delivery systems, potentially expanding its use in pediatric bone healing applications.
- Open Access
Intracellular Delivery of Bone Nanoparticles to Mitigate Irradiation-Induced Damage in Bone Marrow Mesenchymal Stem Cells
Ionizing radiation (IR)-induced bone damage presents a major clinical challenge by impairing bone marrow function and disrupting normal bone remodeling. Bone regeneration depends on bone marrow-derived mesenchymal stem cells (BMSCs), which are highly sensitive to IR that causes DNA damage, oxidative stress, apoptosis, and a shift from osteogenesis to adipogenesis, ultimately leading to bone loss and impaired healing. This study evaluated the therapeutic potential of intracellularly delivered bone-derived nanoparticles (BPs) in mitigating IR-induced BMSCs damage. We found that IR exposure caused significant BMSCs dysfunction, including reduced proliferation, increased apoptosis, persistent DNA damage, and a shift toward adipogenic differentiation. Treatment with BPs led to efficient intracellular uptake, improved cell morphology, enhanced proliferation, reduced apoptosis, and preservation of balanced differentiation capacity. Transcriptomic analysis via RNA sequencing revealed that BPs restored key molecular pathways disrupted by IR, particularly those involved in cell cycle regulation, extracellular matrix (ECM) remodeling, and apoptosis. By reversing these transcriptional impairments, BPs supported genomic stability and the regenerat ive function of BMSCs. Overall, these findings suggest that BPs effectively counteract IR-induced cellular damage and enhance the regenerative capacity of BMSCs, offering a promising therapeutic strategy for radiation -induced skeletal injuries.
Open AccessIntracellular Delivery of Bone Nanoparticles to Mitigate Irradiation-Induced Damage in Bone Marrow Mesenchymal Stem Cells
Ionizing radiation (IR)-induced bone damage presents a major clinical challenge by impairing bone marrow function and disrupting normal bone remodeling. Bone regeneration depends on bone marrow-derived mesenchymal stem cells (BMSCs), which are highly sensitive to IR that causes DNA damage, oxidative stress, apoptosis, and a shift from osteogenesis to adipogenesis, ultimately leading to bone loss and impaired healing. This study evaluated the therapeutic potential of intracellularly delivered bone-derived nanoparticles (BPs) in mitigating IR-induced BMSCs damage. We found that IR exposure caused significant BMSCs dysfunction, including reduced proliferation, increased apoptosis, persistent DNA damage, and a shift toward adipogenic differentiation. Treatment with BPs led to efficient intracellular uptake, improved cell morphology, enhanced proliferation, reduced apoptosis, and preservation of balanced differentiation capacity. Transcriptomic analysis via RNA sequencing revealed that BPs restored key molecular pathways disrupted by IR, particularly those involved in cell cycle regulation, extracellular matrix (ECM) remodeling, and apoptosis. By reversing these transcriptional impairments, BPs supported genomic stability and the regenerat ive function of BMSCs. Overall, these findings suggest that BPs effectively counteract IR-induced cellular damage and enhance the regenerative capacity of BMSCs, offering a promising therapeutic strategy for radiation -induced skeletal injuries.
- 22 April 2025
- Published by IOP Publishing in Biofabrication
- Vol. 17  (3) , 035003
Biofabrication of small-diameter vascular graft with acellular human amniotic membrane: a proof-of-concept study in pig
Expanded polytetrafluoroethylene (ePTFE) grafts are Food and Drug Administration approved and effective for large vessel surgeries but face challenges in smaller vessels (Inner Diameter, ID â©˝ 6 mm) due to reduced blood flow and higher risks of thrombosis, stenosis, and infection. This study developed a vascular graft with an ID of 6 mm from decellularized human amniotic membrane (DAM graft) and compared its performance to ePTFE grafts in a porcine carotid artery model for one month. DAM grafts retained key extracellular matrix structures and mechanical properties post-decellularization, with customizable layers and stiffness to meet specific clinical needs. DAM grafts demonstrated successful carotid artery replacement, showing good surgical feasibility, patency, and post-operative recovery in all animals. In contrast to ePTFE grafts, which exhibited significant neointimal hyperplasia (NIH), poor endothelialization, and inflammation, DAM grafts displayed organized endothelial coverage, smooth muscle alignment, and reduced inflammation, minimizing NIH, thrombosis, and graft failure. These findings position DAM grafts as a promising alternative to synthetic grafts, especially for small-diameter applications. Future research should focus on improving endothelialization, exploring molecular mechanisms, and assessing long-term outcomes to further optimize DAM grafts for clinical use.
- 22 April 2025
- Published by IOP Publishing in Biofabrication
- Vol. 17  (3) , 035003
Biofabrication of small-diameter vascular graft with acellular human amniotic membrane: a proof-of-concept study in pig
Expanded polytetrafluoroethylene (ePTFE) grafts are Food and Drug Administration approved and effective for large vessel surgeries but face challenges in smaller vessels (Inner Diameter, ID â©˝ 6 mm) due to reduced blood flow and higher risks of thrombosis, stenosis, and infection. This study developed a vascular graft with an ID of 6 mm from decellularized human amniotic membrane (DAM graft) and compared its performance to ePTFE grafts in a porcine carotid artery model for one month. DAM grafts retained key extracellular matrix structures and mechanical properties post-decellularization, with customizable layers and stiffness to meet specific clinical needs. DAM grafts demonstrated successful carotid artery replacement, showing good surgical feasibility, patency, and post-operative recovery in all animals. In contrast to ePTFE grafts, which exhibited significant neointimal hyperplasia (NIH), poor endothelialization, and inflammation, DAM grafts displayed organized endothelial coverage, smooth muscle alignment, and reduced inflammation, minimizing NIH, thrombosis, and graft failure. These findings position DAM grafts as a promising alternative to synthetic grafts, especially for small-diameter applications. Future research should focus on improving endothelialization, exploring molecular mechanisms, and assessing long-term outcomes to further optimize DAM grafts for clinical use.
- Open Access
Shear stress inhibits adipocyte differentiation via downregulating lncRNA MALAT1
Adipocyte differentiation plays an important role in bone remodeling due to secretory factors that can directly modulate osteoblast and osteoclast, thus affecting overall bone mass and skeletal integrity. Excessive adipocyte differentiation within bone marrow microenvironment can lead to decreased bone mass, eventually causing osteoporosis. Mechanical microenvironment of bone marrow, including fluid shear, maintains the balance of adipocyte and osteoblast differentiation during bone remodeling. However, how mechanical cues interact with long noncoding RNA (lncRNA) and regulating adipocyte differentiation remains unexplored. In this study, we investigated the mechanosensitive role of lncRNA MALAT1 during mesenchymal stem cells (MSCs) adipocyte differentiation. By applying physiologically relevant shear stress, MSCs experienced morphological changes and adipocyte differentiation differences. Shear stress inhibits MSCs adipocyte differentiation with reduced oil-red-o-stained lipid droplets. Silencing MALATs results in reduced adipocyte differentiation. By leveraging a novel gapmer double stranded locked nuclei acid (dsLNA) nanobiosensor, we showed that shear stress inhibits MALAT1 expression with significantly reduced fluorescence intensity. Our findings suggest that shear stress influences adipocyte differentiation primarily through the downregulation of MALAT1, highlighting a significant interplay between biophysical cues and lncRNAs. This interaction is crucial for understanding the complexities of bone remodeling and the potential therapeutic targeting of lncRNAs to treat bone-related disorders.
Open AccessShear stress inhibits adipocyte differentiation via downregulating lncRNA MALAT1
Adipocyte differentiation plays an important role in bone remodeling due to secretory factors that can directly modulate osteoblast and osteoclast, thus affecting overall bone mass and skeletal integrity. Excessive adipocyte differentiation within bone marrow microenvironment can lead to decreased bone mass, eventually causing osteoporosis. Mechanical microenvironment of bone marrow, including fluid shear, maintains the balance of adipocyte and osteoblast differentiation during bone remodeling. However, how mechanical cues interact with long noncoding RNA (lncRNA) and regulating adipocyte differentiation remains unexplored. In this study, we investigated the mechanosensitive role of lncRNA MALAT1 during mesenchymal stem cells (MSCs) adipocyte differentiation. By applying physiologically relevant shear stress, MSCs experienced morphological changes and adipocyte differentiation differences. Shear stress inhibits MSCs adipocyte differentiation with reduced oil-red-o-stained lipid droplets. Silencing MALATs results in reduced adipocyte differentiation. By leveraging a novel gapmer double stranded locked nuclei acid (dsLNA) nanobiosensor, we showed that shear stress inhibits MALAT1 expression with significantly reduced fluorescence intensity. Our findings suggest that shear stress influences adipocyte differentiation primarily through the downregulation of MALAT1, highlighting a significant interplay between biophysical cues and lncRNAs. This interaction is crucial for understanding the complexities of bone remodeling and the potential therapeutic targeting of lncRNAs to treat bone-related disorders.
- Open Access
- 27 December 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
Bone-derived nanoparticles (BNPs) enhance osteogenic differentiation via Notch signaling
Bone-derived nanoparticles enhance osteogenic differentiation of mesenchymal stem cells through upregulating Dll4 expression.
- 27 December 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
Open AccessBone-derived nanoparticles (BNPs) enhance osteogenic differentiation via Notch signaling
Bone-derived nanoparticles enhance osteogenic differentiation of mesenchymal stem cells through upregulating Dll4 expression.
- Open Access
- 24 December 2024
- Published by Qeios Ltd in Qeios Preprints
Selection of Bone-Targeting Peptides for Therapeutic Intervention: An In Vivo Evaluation and Comparison Study
Hydroxyapatite (HA)-binding peptides are emerging as promising candidates for bone-targeted therapies due to their strong affinity for mineralized tissues and biocompatibility. However, most studies to date have focused on _in vitro_ characterization, providing limited insight into their _in vivo_ performance. This study bridges that gap by evaluating the _in vivo_ behavior of HA-binding peptides D8, E8, YD8, and YE8 using fluorescence imaging to assess their biodistribution in healthy and pathological bone environments. In healthy animal models, D8 demonstrated the strongest binding across mineralized tissues, including the skull, femur, and tibia, while YD8 showed moderate binding. In contrast, E8 and YE8 exhibited limited localization influenced by peptide dosage and binding kinetics. Pathological models, including defective tibia and osteogenesis imperfecta (OIM) mice, revealed preferential accumulation of D8 and YD8 in structurally compromised regions, underscoring their potential for targeting diseased bone microenvironments. Fluorescence imaging, enhanced by spectral unmixing algorithms, proved effective for assessing peptide localization and distribution. These findings highlight the utility of HA-binding peptides for bone-targeted therapies and emphasize the importance of _in vivo_ studies in advancing their therapeutic and diagnostic applications. This work provides a foundation for optimizing peptide designs to improve specificity and efficacy in bone repair and regeneration.
- 24 December 2024
- Published by Qeios Ltd in Qeios Preprints
Open AccessSelection of Bone-Targeting Peptides for Therapeutic Intervention: An In Vivo Evaluation and Comparison Study
Hydroxyapatite (HA)-binding peptides are emerging as promising candidates for bone-targeted therapies due to their strong affinity for mineralized tissues and biocompatibility. However, most studies to date have focused on _in vitro_ characterization, providing limited insight into their _in vivo_ performance. This study bridges that gap by evaluating the _in vivo_ behavior of HA-binding peptides D8, E8, YD8, and YE8 using fluorescence imaging to assess their biodistribution in healthy and pathological bone environments. In healthy animal models, D8 demonstrated the strongest binding across mineralized tissues, including the skull, femur, and tibia, while YD8 showed moderate binding. In contrast, E8 and YE8 exhibited limited localization influenced by peptide dosage and binding kinetics. Pathological models, including defective tibia and osteogenesis imperfecta (OIM) mice, revealed preferential accumulation of D8 and YD8 in structurally compromised regions, underscoring their potential for targeting diseased bone microenvironments. Fluorescence imaging, enhanced by spectral unmixing algorithms, proved effective for assessing peptide localization and distribution. These findings highlight the utility of HA-binding peptides for bone-targeted therapies and emphasize the importance of _in vivo_ studies in advancing their therapeutic and diagnostic applications. This work provides a foundation for optimizing peptide designs to improve specificity and efficacy in bone repair and regeneration.